Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma

Study acronym: RIT in MTC
StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study Identification, Study Status, Referencesv4
  2. Trial status: Active, Not Recruiting to Completed
    • Study sites: 13 to 11
    • Primary completion date: Jan 2011
    v3
  3. Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jan 2011
    • Site details revised at 13 of 13 sites
    v2
  4. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)
Trial Details
NCT Number NCT00467506
Lead Sponsor Nantes University Hospital
Conditions
(from sponsor)		 Thyroid Neoplasms
Related terms Thyroid Neoplasms
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov